Atypical posterior reversible encephalopathy syndrome secondary to dasatinib.

with skin involvement (proven by skin biopsy) has been reported twice. Other differential diagnoses of HSTCL include aggressive natural killer cell leukemia (typically negative for surface CD3 on flow cytometry) and T-lymphoblastic leukemia [dim expression of CD45 and surface CD3 with expression of immaturity markers (TdT/CD34/CD1a)] [4, 6, 8]. The disease has an aggressive course, and most cases will relapse. Moreover, there is no known optimal therapy [1, 2, 7]. With conventional chemotherapy, complete remission is uncommon, and most patients die within two years of diagnosis [5, 9]. Long-term remission can be achieved by allogeneic stem cell transplantation, and studies have suggested that both autologous and allogeneic transplants may confer a potential cure for the disease with an estimated 3 years overall survival after allogeneic transplantation of 56% [2, 8]. One major limitation regarding staging and assessing the extent of lymphoma is the unavailability of bone and PET scans for the patient at diagnosis, which makes assessment of response for chemotherapy and evaluation for achievement of remission challenging.